$ARDX Transparency matters. When a name like Ardelyx gets a notable Jefferies note questioning Q2 Ibsrela momentum vs. the reiterated guidance, proactive color from the company helps. Silence invites speculation and can amplify moves in either direction. Q1 was solid (IBSRELA +58% YoY), and the full-year guide stands. But if early indicators show any pressure whether from competition, reimbursement nuance, seasonality, or pull-through variability, then an interim update on demand metrics would let investors recalibrate rather than wait. Quarterly results in GI can be lumpy; the trend and management’s read on it are what matter most. Strong IR is cheap insurance. It reduces information asymmetry, dampens unnecessary volatility, and signals that leadership treats shareholder commu
View on X ↗